Article info

PDF

Extended report
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Authors

  1. Correspondence to Dr Yoshikazu Nakaoka, Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka 565-8565, Japan; ynakaoka{at}ncvc.go.jp
View Full Text

Citation

Nakaoka Y, Isobe M, Takei S, et al
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Publication history

  • Received 1 June 2017
  • Revised 25 October 2017
  • Accepted 31 October 2017
  • Published online 30 November 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.